The role of low dose IL-2 in preventing secondary autoimmunity after alemtuzumab in Multiple Sclerosis

Project: Research

Project Details

AcronymLITMUS Treg
StatusFinished
Effective start/end date30/08/201929/11/2022

Collaborative partners

Funding

  • Wellcome Trust: £4,926.56